Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 1, 2022
Distillery Therapeutics

Degrading FOXO1 via KIND2 inhibition for NAFLD

BioCentury | Jan 31, 2020
Distillery Therapeutics

FERMT2 identified as target in renal fibrosis

BioCentury | Mar 13, 2019
Distillery Therapeutics

Inhibiting FERMT2 for lung cancer

BioCentury | Jul 13, 2017
Preclinical News

FERMT2 identified as potential breast cancer target

Items per page:
1 - 4 of 4